 The FDA has granted Orphan Drug Designation to Lantern Pharma Incs NASDAQ: LTRN LP-184 for glioblastoma multiforme GBM and other malignant gliomas. The news follows the recent announcement of the FDA granting LP-184 Orphan Drug tag for pancreatic cancer. 